Therefore, MOS, TPL2 and ERK1/2 inhibitors may be therapeutically useful for treating BCR::ABL1‐independent dasatinib‐resistant CML. Here, MAPK3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.